RO24-7429 (TAT INHIBITOR) PILOT-- ORAL SOLUTION IN HIV POSITIVE PATIENTS

RO24-7429（TAT 抑制剂）试验——HIV 阳性患者的口服溶液

• 批准号: 3847419
• 负责人: PAUL S LIETMAN
• 金额: --
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3847419
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; clinical trials; drug screening /evaluation; genetic transcription; human subject; human therapy evaluation; transcription factor; virus replication

The Human Immunodeficiency Virus (HIV) genome contains a number of genes that regulate viral replication. Control of the activity of these genes and their encoded proteins represents a potential target for development of new antiretroviral drugs. The TAT (transactivator of transcription of HIV) inhibitor, RO 24-7429, is the first compound for clinical testing that uses this approach for therapy of HIV infection.

人类免疫缺陷病毒（HIV）基因组包含许多基因， 调节病毒复制控制这些基因的活性 它们编码的蛋白质是一个潜在的发展目标 新的抗逆转录病毒药物。达特（转录反式激活因子 HIV）抑制剂RO 24-7429是第一个用于临床试验的化合物 用这种方法治疗艾滋病病毒感染。